Retrospective Study
Copyright ©The Author(s) 2023.
World J Clin Cases. Oct 6, 2023; 11(28): 6688-6697
Published online Oct 6, 2023. doi: 10.12998/wjcc.v11.i28.6688
Table 1 Baseline clinical profiles of enrolled individuals
Disease
n
Sex (male/female)
Age (yr)
Systemic lupus erythematosus1388/13011-77
Sicca syndrome482/4618-83
Rheumatoid arthritis5014/3620-85
Scleroderma123/938-69
Dermatomyositis227/159-78
Healthy controls13031/9914-79
Table 2 Detection rate of antinuclear antibody spectrum, n (%)
ItemsChemiluminescence method
Immunochemistry
χ2P value
SLE
SS
Other
Total
SLE
SS
Other
Total
Anti-double-stranded DNA (dsDNA) antibody69 (50.00)5 (10.42)3 (3.57)77 (28.52)61 (44.20)4 (8.33)3 (3.57)68 (25.19)0.764 0.382
Anti-histone (Histone) antibody32 (23.19)4 (8.33)5 (5.95)41 (15.19)35 (25.36)4 (8.33)7 (8.33)46 (17.04)0.343 0.558
Anti-nucleosome (Nuc) antibody40 (28.99)1 (2.08)4 (4.76)45 (16.67)36 (26.09)1 (2.08)3 (3.57)40 (14.81)0.349 0.555
Anti-Smith (Sm) antibody18 (13.04)1 (2.08)2 (2.38)21 (7.78)17 (12.32)0 (0.00)1 (1.19)18 (6.67)0.249 0.618
Anti-ribosomal P protein (Rib-P) antibody38 (27.54)2 (4.17)0 (0.00)40 (14.81)49 (35.51)2 (4.17)0 (0.00)51 (18.89)1.599 0.206
Anti-sicca syndrome A (Ro60) antibody82 (59.42)40 (83.33)14 (16.67)136 (50.37)85 (61.59)36 (75.00)13 (15.48)134 (49.62)0.030 0.863
Anti-sicca syndrome A (Ro52) antibody77 (55.80)37 (77.08)19 (23.46)133 (49.26)79 (57.25)36 (75.00)21 (25.00)136 (50.37)0.067 0.796
Anti- sicca syndrome (SSB) antibody19 (13.77)18 (37.50)12 (14.29)49 (18.15)20 (14.49)19 (39.58)11 (13.10)50 (18.52)0.012 0.911
Anti-centromere protein B (Cenp-B) antibody11 (7.97)4 (8.33)2 (2.38)17 (6.30)8 (5.80)3 (6.25)2 (2.38)13 (4.81)0.565 0.452
Anti-DNA topoisomerase 1 (Scl-70) antibody5 (3.62)0 (0.00)6 (7.14)11 (4.07)4 (2.90)0 (0.00)6 (7.14)10 (3.70)0.050 0.824
Anti-histidyl tRNA synthetase (Jo-1) antibody0 (0.00)0 (0.00)1 (1.19)1 (0.37)1 (0.72)0 (0.00)1 (4.62)2 (0.74)0.335 0.563
Anti-mitochondrial M2 (AMA-M2) antibody2 (1.45)1 (2.08)3 (3.57)6 (2.22)2 (1.45)0 (0.00)3 (3.57)5 (1.85)0.093 0.761
Table 3 Agreement rate of antinuclear antibody spectrum (%)
Items
Positive agreement rate
Negative agreement rate
Total agreement rate
Kappa
P value
Anti-double-stranded DNA (dsDNA) antibody89.71 92.08 91.48 0.783< 0.05
Anti-histone (Histone) antibody82.61 98.66 95.93 0.849< 0.05
Anti-nucleosome (Nuc) antibody90.00 96.09 95.19 0.819< 0.05
Anti-Smith (Sm) antibody83.33 97.62 96.67 0.751< 0.05
Anti-ribosomal P protein (Rib-P) antibody64.71 96.80 90.74 0.671< 0.05
Anti-sicca syndrome A (Ro60) antibody93.28 91.91 92.59 0.852< 0.05
Anti-sicca syndrome A (Ro52) antibody91.18 92.59 92.22 0.844< 0.05
Anti- sicca syndrome (SSB) antibody88.00 97.73 95.93 0.864< 0.05
Anti-centromere protein B (Cenp-B) antibody92.31 98.05 97.78 0.788< 0.05
Anti-DNA topoisomerase 1 (Scl-70) antibody80.00 98.85 98.15 0.752< 0.05
Anti-histidyl tRNA synthetase (Jo-1) antibody50.00 100.00 99.63 0.665< 0.05
Anti-mitochondrial M2 (AMA-M2) antibody80.00 99.25 98.89 0.722< 0.05
Table 4 Diagnostic performance of antibodies detected by chemiluminescence assay and line immunoassay for systemic lupus erythematosus
AntibodiesChemiluminescence method
Line immunoassay
AUC
95%CI
AUC
95%CI
Anti-double-stranded DNA (dsDNA) antibody0.935 0.907-0.9620.905 0.871-0.940
Anti-histone (Histone) antibody0.508 0.436-0.5800.513 0.441-0.585
Anti-nucleosome (Nuc) antibody0.837 0.788-0.8860.829 0.780-0.879
Anti-Smith (Sm) antibody0.941 0.914-0.9680.907 0.872-0.943
Anti-ribosomal P protein (Rib-P) antibody0.776 0.721-0.8310.791 0.738-0.844
Anti-sicca syndrome A (Ro60) antibody0.953 0.931-0.9750.945 0.921-0.969
Anti-sicca syndrome A (Ro52) antibody0.946 0.920-0.9720.929 0.900-0.958
Anti- sicca syndrome (SSB) antibody0.650 0.584-0.7160.661 0.596-0.727
Anti-centromere protein B (Cenp-B) antibody0.811 0.761-0.8610.787 0.733-0.841
Anti-DNA topoisomerase 1 (Scl-70) antibody0.783 0.727-0.8380.740 0.681-0.800
Anti-histidyl tRNA synthetase (Jo-1) antibody0.821 0.769-0.8740.781 0.722-0.841
Anti-mitochondrial M2 (AMA-M2) antibody0.895 0.844-0.9470.920 0.883-0.957